Category Archives: Diagnostics

Biotech, Diagnostics, Health Products, Healthcare, Healthcare Products, Healthcare Solutions, Public Health

AMBROSIA, a new HORIZON-RIA project, aims to develop a portable diagnostic unit for intelligent sepsis diagnosis

Leave a comment

ATHENS, 9-May-2023 — /EuropaWire/ — AMBROSIA (http://ambrosia-h2022.eu/) is a new ambitious HORIZON Research and Innovation Action project that was granted under the call of “Digital and emerging technologies for competitiveness and fit for the green deal” and the topic “HORIZON-CL4-2022-DIGITAL-EMER-GING-01-03: Advanced multi-sensing systems”. AMBROSIA envisions to develop a portable diagnostic unit for intelligent sepsis diagnosis at the point-of-care (PoC).

Sepsis is a life-threatening whole-body inflammatory reaction caused by a severe infection. With mortality rates around 35%, sepsis is responsible for 11 million deaths worldwide every year. In economic terms, sepsis represents a primary cost of hospitalization in developed regions, expending up to €9 billion/year only in Germany. The window of opportunity for sepsis management is in hours: the chance of survival drops by 7.6% each hour of disease progression until an appropriate treatment is started. However, early and accurate sepsis detection is hampered due to: i) complex diagnostic criteria requiring screening of multiple targets, (ii) time-consuming methods for identifying the bacterial causes of sepsis, (iii) specimen transfers in centralized laboratories. Meeting this challenging framework can only be accomplished through the adoption of real-time and label-free sensor technologies incorporated in PoC platforms.

This is exactly where AMBROSIA steps in to transform integrated plasmo-photonic RI sensors into a disruptive solution for sepsis diagnosis at the point of care that will offer multiplexed (within a single test) quantification of multiple protein biomarkers and bacteria within a few minutes, providing also real-time disease stage classification and enabling a rapid and precise decision making for medical actuation. Specifically, AMBROSIA objectives include:

1. Development of multi-channel label-free CMOS plasmo-photonic sensors with high-sensitivity and resilience to noise.
2. Hetero-integration of InP-on-SiN through micro-transfer printing (μTP).
3. Development of an AI-based electro-optical read-out exploiting ultra-low power photonic Deep Neural Networks for disease classification.
4. Development of a PoC sepsis diagnostic unit.
5. Experimental validation of AMBROSIA sepsis diagnostic system with real samples.

The project is coordinated by the Aristotle University of Thessaloniki, Greece, and is scheduled to run for 4 years bringing together 12 partners strategically compiled from strong industrial and academic organizations including: (a) 4 universities, Aristotle University of Thessaloniki (GR), University of Bourgogne (FR), University of Southampton (UK), and University of Ioannina (GR), (b) 2 research institutes, the Catalan Institute of Nanoscience and Nanotechnology (ES), and the Vall d’Hebron Research Institute (ES), and (c) 6 companies, Ligentec (CH), SMART PHOTONICS BV (NL), X-Celeprint (IE), Argotech (CZ), microLIQUID (ES), and Biopix DNA Technology P.C. (GR).

About AMBROSIA

A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE

Project ID:101093166
Call: HORIZON-CL4-2022-DIGITAL-EMERGING-01
Type of Action: HORIZON-RIA
Start Date: 01 Jan 2023
Duration: 48 months
Estimated Project Cost: €4,999,612.17
Requested EU Contribution: €3,689,509.66

Website: http://ambrosia-h2022.eu/

About BIOPIX-T

BIOPIX DNA TECHNOLOGY P.C. (https://biopix-t.com)  was founded in December 2019 in order to commercialize a novel molecular diagnostic method, developed by the founding team, for the detection of nucleic acids at the point-of-care. The company targets multiple healthcare-diagnostics related markets through the production of standardized assays for detection and monitoring of Infectious Diseases and Companion Diagnostics. Our mission is to offer portable diagnostic devices to every potential end-user, regardless of financial status, geographical location and training.

SOURCE: EuropaWire

Biotech, Cardiac Surgery, Diagnostics, Healthcare, Healthcare Professionals, Healthcare Solutions, Therapies

First patient enrolled in an international multicenter clinical study for non-invasive cardiac resynchronization therapy

Leave a comment

BOLZANO/ BOZEN, Italy, 19-Mar-2023 — /EPR HEALTHCARE NEWS/ — XSpline SPA, a start-up company incorporated in Bolzano (Italy) and the Ordensklinikum Linz Elisabethinen Hospital in Linz (Austria) today announced the first patient enrolled in a clinical study (ClinicalTrials.govID: NCT05327062) for the cardiac resynchronization therapy (CRT) guided by non-invasive electrical and venous anatomy assessment.  The international multicenter prospective study will include 150 patients from 16 centers in the U.S. and Europe.

XSpline Cloud provides a cloud-based non-invasive cardiac panoramic mapping technology to select individual CRT treatment strategy and predict outcomes.

Fast and fully automatic Artificial Intelligence based epi- and endocardial segmentation of cardiac structures, including coronary sinus veins, provides clear understanding of individual patient’s anatomy. The electrical assessment is based on a 3D panoramic electro-anatomical map based on 12 -lead ECG only, without requiring multichannel ECG recording or any kind of body surface potential mapping. XSpline Cloud is the first system in the world with AI based identification of the correct target zone for LV lead implantation.

The cloud-platform guarantees full operability with existing clinical standards and data formats; it supports IHE profiles, HL7 FIHR, DICOM, and a broad range of ECG formats. The platform also provides embedded medical grade visualization tools, such as an integrated multimodality DICOM viewer, an ECG viewer with measurement capabilities, a high-performance 3D viewer for segmented cardiac structures and electro- anatomical maps as well as an interactive navigator for LV lead placement.

Dr. Georgios Kollias, M.D., is the principal investigator for the clinical trial in Austria and performed the first procedure on a 71-year-old patient with ESV LV of 154 ml and EF LV of 20%.

“The XSpline Cloud software provides a unique approach to selecting an individualized CRT treatment strategy. It is a comprehensive tool for successful CRT implantation that can also predict outcomes, making the implantation procedure faster, easier, and safer for the patient. We are very pleased to start using this tool in our clinic”, said Dr. Kollias.

“XSpline SPA is supported by an international R&D team of skilled clinicians, mathematicians, and biomedical engineers with the shared goal of improving patient care. We think that the real-time visualization of each patient’s individual anatomy, the precise non-invasive electro-anatomical endo- and epicardial activation map and the interactive navigator will help to increase CRT responders”, said Mr. Werner Rainer, CEO of the company.

XSpline Cloud is an investigational device and not yet approved for commercial use.

SOURCE: EuropaWire

Biotech, Diagnostics, Diseases, Healthcare, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Pharmaceuticals, Public Health, Society

New AI-powered predictive algorithm offers unprecedented accuracy in diagnosing NASH and liver fibrosis staging

Leave a comment

BOSTON, MA, United States, 18-Jul-2022 — /EPR HEALTHCARE NEWS/ — Metadeq Inc., a global NASH and metabolic diseases diagnostics company, today announced a breakthrough non-invasive blood test that utilizes two novel circulating proteins to accurately diagnose Non-alcoholic steato-hepatitis (NASH) and liver fibrosis, and can score the stages of both diseases, without the need for invasive liver biopsy. The study which details the new blood test – just revealed in Gut, a leading hepatology and gastroenterology journal published by BMJ – was led by King’s College London Professor Geltrude Mingrone, in collaboration with Metadeq.

Approximately one in four people worldwide, or approximately two billion people, have Non-alcoholic fatty liver disease (NAFLD) and therefore are at risk of developing NASH. NASH is the most severe form of NAFLD, a silent disease associated with fatty deposit build-up of the liver. NASH leads to advanced liver diseases such as liver fibrosis (scarring), cirrhosis, and liver cancer, and may ultimately result in death. The annual cost to the US healthcare system alone has been estimated to be over $100 billion per year.

Currently, the only way to diagnose NASH is through the standard of diagnosis, invasive liver biopsy, which is expensive and is associated with significant complications and discomfort. Until now, no reliable blood test has been developed for NASH, nor liver fibrosis. Most importantly, no available test can define the severity (stage), or monitor the progression, of either NASH or liver fibrosis.

Professor Geltrude Mingrone from the School of Cardiovascular and Metabolic Medicine & Sciences at King’s College London, who is one of the most widely cited and influential researchers globally for metabolic diseases and disorders, set out to discover a more accurate liquid biopsy test in support of patient care and in collaboration with Metadeq. The resulting study was published today in leading journal, Gut.

This study identified two novel protein biomarkers, PLIN2 and RAB14, to assist in the diagnosis of patients with NASH and/or liver fibrosis. The ability of these proteins to detect both diseases was tested in cohorts with either NASH and/or liver fibrosis that were confirmed with liver biopsy, the current standard of diagnosis.

“This blood test will allow researchers and clinicians to define the prevalence of NASH across populations, including children and adolescents, avoiding the need for invasive liver biopsy,” said Professor Mingrone. “Critically, it will allow care-givers to monitor the efficacy of NASH treatments over time, reducing screen failures and helping generate better drugs.”

“Since HEPAR-QTM is the only diagnostic modality that can diagnose NASH and fibrosis staging we expect it to be instrumental in the development of new therapeutics for the management of patients,” said Frank Jaksch, Chairman of Metadeq. “We believe that HEPAR-QTM will advance for the benefit of patients the problem of regular screening, that has resulted in late drug failures during clinical trials, since it is now possible to accurately measure the severity of disease in a non-invasive manner.”

 

The Metadeq predictive algorithm, which uses A.I., provided unprecedented sensitivity (88-95%), specificity (90-100%), and overall accuracy (92-93%) for NASH, and also has near-perfect sensitivity (99%-100%), specificity (90%-96%), and accuracy (98%-99%) for liver fibrosis.

The test results show that the proteins can provide rapid and cost-effective testing to combat the growing epidemic of NASH and liver fibrosis. This could be an invaluable tool in diagnosing and monitoring cases of liver diseases, allowing people to receive earlier treatment, from lifestyle adjustments to surgical and pharmacological interventions.

Currently no NASH drug has been approved by either the FDA or EMA, which may be a direct result of the lack of an accurate, reliable, and non-invasive test. More than 65% of patients who enroll in clinical trials for NASH-related therapies are found to be ineligible for the trial due to screen failure, which causes major monetary losses to companies developing and testing NASH drugs. The improved accuracy and ability to detect NASH staging will help in identifying and enrolling the appropriate people in clinical trials, speeding up the development of NASH drugs.

About Metadeq
Metadeq Corp. is a diagnostics company that provides innovative liquid biopsy solutions for liver and metabolic diseases. For the first time, Metadeq allows people to measure the whole spectrum of liver diseases – from NAFLD, to NASH, and liver fibrosis – with a blood test. www.metadeq.com

SOURCE: EuropaWire

Biotech, Diagnostics, Disorders, Healthcare, Healthcare Information, Pharmaceuticals, Psychiatry, Psychologist, Public Health, Society

Kenneth Research: Increasing Concern for Mental Health Disorders to Drive Market Growth for Mental Health Software and Devices

Leave a comment

NEW YORK, 21-Mar-2022 — /EPR HEALTHCARE NEWS/ — Every year, over 7 Million people are known to die by suicide, one of the major concerns of mental health, according to the statistics by the World Health Organization (WHO). Calculatedly, this comes to one person every 40 seconds. Moreover, in the year 2019, suicide accounted for 1.3% of the total number of deaths around the globe. On the other hand, mental health disorders, such as depression, affected 3.8% of the global population, or around 280 Million people. This included 5.0% adults and 5.7% aged adults above 60 years of age.

Kenneth Research recently released a report titled “Global Mental Health Software and Devices Market” which includes a detailed analysis of the market dynamics along with the impact of COVID-19 on the market growth during the forecast period, i.e., 2021-2030. The report also includes the regulatory and standard landscape, and in-depth research about the market growth across the five major regions, i.e., North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

In Europe, Austria (24 males, 5.6 females), Belgium (23 males, 8.6 females), France (22 males, 5.9 females), Finland (22.9 males, 7.6 females), Germany (17.3 males, 4.8 females), Sweden (17.7 males, 7.0 females), Netherlands (15.7 males, 7.0 females), has shown the highest number of death rates and self-harms per 100,000 inhabitants.

As COVID19 sweeps the global economies, Europe is one of the worst hit since 2020. As new COVID guidelines, lockdown and restriction comes into force, economies have reported elevated cases of anxiety and stress. Especially quarantine and its ill impacts have pushed levels of loneliness, depression, drug use, alcohol consumption, suicidal behavior and self-harm are pushed to another level.

Request for Research Report Sample- https://www.kennethresearch.com/report-details/mental-health-software-and-devices-market/10352350

Mental health is a major concern globally and with the rising prevalence of different types of such disorders in recent years, as well as with the growing awareness for these diseases by governmental bodies, the disease has been included in the list of 17 Sustainable Development Goals (SDGs) of the United Nations. Moreover, the situation for the disease has also gained massive focus, especially to treat the elderly population. This can be attributed primarily to the increasing elderly population count over the past few years, and the growing awareness for mental health and well-being amongst these age groups. In the other statistics by the WHO, the proportion of the population of age 60 years and over around the world is expected to double from 12% to 22% between 2015 and 2050. The statistics further stated that over 20% of these adults suffered from a mental or neurological disorder, and 6.6% of all disabilities amongst these population groups accounted for such disorders. Additionally, around 5% and 7% of these populations had been affected with dementia and depression respectively, which are the two most common mental and neurological disorders.

The global mental health software and devices market generated a revenue of USD 3883.94 Million in the year 2020 and is further expected to grow with a CAGR of 13.28% during the forecast period and touch a value of USD 13367.12 Million by the end of 2030. The growth of the market can primarily be attributed to the growing need for advanced patient monitoring and patient management applications amongst healthcare service providers for those treating mental disorders, backed by the surge in the number of mental health patients worldwide. Besides this, the increasing number of these patients is expected to drive the need for advanced devices which can help for early diagnosis and treatment, therefore contributing to the market growth in the coming years. For instance, the prevalence of dementia, which is known for deteriorating the memory, thinking, behavior, and the ability of the patients to perform everyday activities, is expected to increase to 82 Million by 2030, and further touch 152 Million by 2050, according to the statistics by the WHO. On the other hand, according to the statistics by United Nations Children’s Fund (UNICEF), in the year 2019, between the ages 10 and 14, 34,840,000 female adolescents and 44,647,000 male adolescents suffered from mental disorders. Moreover, between the ages 15 and 19, 41,712,000 female adolescents and 44,563,000 male adolescents had suffered from the same disorder. The surge in these cases is expected to boost the demand for diagnostic devices for the treatment of the disorder, and in turn, drive the market growth.

Request for Research Report Sample- https://www.kennethresearch.com/report-details/mental-health-software-and-devices-market/10352350

The growth of the global mental health software and devices market can also be attributed to the increasing number of government initiatives that focus on maintaining good mental health and well-being of the individuals of nations worldwide. For instance, in May 2013, during the 66th World Health Assembly, the Comprehensive Mental Health Action Plan 2013-2020 developed by the WHO was adopted by the Ministers of Health of the 194 Member States. This action plan was further extended until 2030 in the year 2019, during the 72nd World Health Assembly. On the other hand, according to the statistical report titled “Mental Health Atlas 2020”, published by the WHO, 75% of the Member States had a stand-alone policy or plan for mental health. This was an increase from 68% in the year 2014.

Additionally, the statistics also stated that 57% of the Member States had a stand-alone mental health law. This was an increase from 51% in the year 2014. Besides this, since 2017, 46% of the WHO Member States had updated their health policy or plan, while 27% of them had updated their law regarding mental health.

The global mental health software and devices market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Out of the market in these regions, the market in North America generated the largest revenue of USD 1557.47 Million in the year 2020 and is further expected to touch USD 5382.17 Million by the end of 2030. One of the major factors anticipated to drive the growth of the market in the region is the increasing awareness for mental health and the rising need amongst healthcare service providers to improve their services to patients who are suffering from the disease. For instance, according to the statistics by the National Alliance on Mental Illness (NAMI), in the United States, in the year 2020, 1 in 5 U.S. adults experiences a mental illness, while 1 in 20 experienced a serious one, and 1 in 15 experienced both a substance use disorder and mental illness. In addition to this, 26.3 Million adults in the nation received virtual mental health services during the COVID-19 pandemic. Amongst those who received these services, 17.7 Million people experienced delays or cancellations in appointments, while 7.3 Million experienced delays in getting prescriptions. Moreover, 4.9 Million people were unable to access needed care. The market in the region is segmented by country into the United States and Canada. Out of the market in these countries, the market in the United States is expected to hold the largest revenue by the end of 2030 and also grow with the highest CAGR of 13.36% during the forecast period.

Request for Research Report Sample- https://www.kennethresearch.com/sample-request-10352350

On the other hand, the mental health software and devices market in Europe generated a revenue of USD 1265.71 Million in the year 2020 and is further expected to touch USD 4360.54 Million by the end of 2030, by growing with a CAGR of 13.31% during the forecast period. One of the major factors anticipated to drive the growth of the market in the region is the growing reforms in the diagnosis of mental health. For instance, on the 13th of May, 2019, the Parliamentary Assembly of the Council of Europe (PACE) on Social Affairs, Health, and Sustainable Development, had urged the member States of the Council of Europe to end coercive practices in mental health settings and further adopt a human rights-based approach which is respectful of medical ethics. The market growth in the region can also be attributed to the increasing government initiatives to improve behavioral health services and the surge in the adoption of electronic health records (EHR). The market in the region is further segmented by country into Germany, France, United Kingdom, Italy, Spain, Russia, Netherlands, and the Rest of Europe. Amongst the market in these countries, the market in France is expected to generate the largest revenue of USD 988.54 Million by the end of 2030 and further grow with a CAGR of 13.75% during the forecast period. Additionally, the market in the nation generated a revenue of USD 275.93 Million in the year 2020. Furthermore, the market in Germany registered the second-largest revenue of USD 249.35 Million in the year 2020 and is further expected to touch USD 911.35 Million by the end of 2030.

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

The global mental health software and devices market is segmented by delivery model into subscription model and ownership model. Amongst these segments, the subscription model segment is projected to garner the largest revenue of USD 2442.34 Million by the end of 2022. Further, the segment is also expected to grow with the highest CAGR of 11.82% during the forecast period. In North America, the segment is expected to garner the highest market share by the end of 2030, while in Europe, the segment is projected to garner the largest revenue of USD 762.37 Million by the end of 2022.

The global mental health software and devices market is further segmented by end user into community clinics, hospitals, private practices, and home care settings. Among these segments, the community clinics segment registered the largest revenue of USD 1644.62 Million in the year 2020 and is further expected to touch a revenue of USD 5667.35 Million by the end of 2030. In North America, the segment generated the largest revenue of USD 660.52 Million in the year 2020 and is further projected to reach USD 2285.27 Million by the end of 2030, by growing with a CAGR of 13.35% during the forecast period. On the other hand, in the Asia Pacific, the segment is anticipated to garner the largest revenue of USD 1124.71 Million by the end of 2030, up from a revenue of USD 317.70 Million in the year 2020. Moreover, in Japan, the segment is expected to garner the largest revenue of USD 244.73 Million and further grow with a CAGR of 14.34% during the forecast period.

The global mental health software and devices market is also segmented on the basis of component, functionality, and mode of access.

Global Mental Health Software and Devices Market, Segmentation by Component

  • Software
    o Integrated Software
    o Standalone Software
  • Devices

Global Mental Health Software and Devices Market, Segmentation by Functionality

  • Clinical Functionality
    o Electronic Health Records (EHR)
    o Clinical Decision Support (CDS)
    o Care Plans/Health Management
    o E-Prescribing
    o Telehealth
  • Administrative Functionality
    o Patient/Client Scheduling
    o Document/Image Management
    o Case Management
    o Workforce Management
    o Business Intelligence
  • Financial Functionality
    o Revenue Cycle Management
    o Managed Care
    o Accounts Payable/General Ledger

Global Mental Health Software and Devices Market, Segmentation by Mode of Access

  • Desktops/Laptops
  • Tablets/Smartphone

Some of the prominent industry leaders in the global mental health software and devices market that are included in our report are Cerner Corporation, Netsmart Technologies, Inc., Qualifacts Systems, Inc., Valant, NXGN Management, LLC, Core Solutions, Inc., Holmusk USA, Inc., The Echo Group, Welligent, Inc., Credible Behavioral Health, Inc., IBM, and others.

Request for Research Report Sample- https://www.kennethresearch.com/sample-request-10352350

 

SOURCE: EuropaWire

Cardiology, Diagnostics, Healthcare, Healthcare Services, Healthcare Software, Healthcare Solutions

MEDIS expands into new areas of cardiovascular disease with the acquisition of Italian medtech company AMID

Leave a comment

LEIDEN, Netherlands, 11-May-2020 — /EPR HEALTHCARE NEWS/ — MEDIS, a leading developer and supplier of software applications for image-based diagnosis and quantitative assessment of cardiovascular disease, today announced that it acquired Advanced Medical Imaging Development S.r.l. (AMID), a developer and supplier specialized in cardiovascular mechanics and innovative image processing in ultrasound and other modalities. The strategic acquisition will expedite MEDIS’ expansion in new areas of cardiovascular disease, and secure MEDIS’ access to key technologies to further enhance its innovative portfolio of post-processing solutions for X-ray, MR, CT, IVUS, OCT and US devices.

The acquisition of AMID, based in Sulmona (Italy), will further increase MEDIS’ share in the cardiovascular market. “This acquisition expands our product portfolio and brings in new sales channels. The combination of AMID’s products with our product and services portfolio will enable us to provide our customers a unique and more complete multi-modal offering for cardiovascular imaging analysis”, said Hans Brons, CEO of MEDIS.

“As part of MEDIS we will have significantly more leverage to position our portfolio of innovative technologies in the global market for cardiovascular imaging software,” commented Giovanni Tonti, CEO of AMID. “Our technology offerings will allow MEDIS to complement and further enhance its already impressive suite of clinical offerings and spur innovation.”

“MEDIS and AMID have already had an excellent cooperation for over five years, both commercially and in product development. I am very excited about our access to the unique know-how and innovative power of AMID’s founders and their technology, and to intensify the cooperation leading to new solutions that ultimately will benefit the patients“ says Hans Reiber, founder and CSO of MEDIS.

MEDIS will leverage AMID’s proprietary state-of-the-art software and know-how to provide even more sophisticated cardiac and cardiovascular imaging software solutions to its customers. “The integration of both companies will take place over the next months. We expect to significantly strengthen our power to innovate and are very excited about our new relationships with AMID’s existing OEMs and sales channels” added Hans Brons. “Our new customers will continue to receive the same high quality of service which they have come to expect.”

AMID, which will continue to operate under that name is now a wholly owned subsidiary of MEDIS.

Over the last 6 months Van Herk Ventures has made significant further equity investments in MEDIS with the aim to help accelerate the growth of the company and to enable the acquisition of AMID.

“With this investment, Van Herk Ventures enables us to further expand on our position as an independent vendor of high specialty software and a leader in this industry,” stated Hans Brons, CEO of MEDIS.

“We have been intrigued by the broad spectrum of innovations in the cardiovascular imaging domain that MEDIS has created and commercialized over the years, and in particular the more recent exciting and disruptive opportunities in the field of interventional cardiology.

MEDIS has been recognized worldwide as a company that develops high quality software, listening to the needs of the clinicians and researchers and supporting them with new and expanded applications. We believe that there is a great upwards potential in MEDIS and we like to stimulate these developments and see the company grow to the next level. We are therefore very excited about the MEDIS acquisition of AMID,” said Dharminder Chahal, managing director of Van Herk Ventures.

SOURCE: EuropaWire

Biotech, Diagnostics, Healthcare, Healthcare Products, Healthcare Services, Healthcare Solutions, Pharmaceuticals

Mr RICHARD GUILLAUME IS APPOINTED TO THE DIAFIR BOARD OF DIRECTORS

Leave a comment

RENNES, FRANCE, 2019-Apr-08 — /EPR HEALTHCARE NEWS/ — DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions in nonalcoholic steatohepatitis (NASH) and septic arthritis announces today the appointment of Mr Richard Guillaume to its Board of Directors.

Mr Guillaume has a wide experience of over 30 years in international management and operations in the pharmaceutical industry as well as in the medtech. Drawing on his experience and knowledge in the field of medical devices and diagnosis, Mr Guillaume will advise and help the Company in its development.

Alongside his role at Diafir, Richard Guillaume has been the General Manager of Echosens from 2008 until 2013. He was previously Executive Vice President Global Sales and Marketing at Blatchford, a UK medical device company. He was also member of the board. Prior, he held various positions such as Director Global Marketing of Abbott International in Chicago and Director Category Development Europe of Mead Johnson. Richard holds a Master in Business Administration from Poitiers University and a DESS in Marketing from Paris Dauphine completed by a general management program at INSEAD.

 

Via EPR Network
More Healthcare press releases

Business of Medicine, Cardiology, Diabetes, Diagnostics, Gynecology, Health Products, Healthcare, Healthcare Information, Healthcare Products, Infertility Treatment, Pharmaceuticals

Europe Home Diagnostics Market: Growth in Pregnancy and Ovulation Predictor Test Kits Sales Encouraging

Leave a comment

DUBLIN 2, Ireland, 18-Oct-2018 — /EPR HEALTHCARE NEWS/ — The European home diagnostics industry is realigning to foster integration with the broader customer-centric healthcare services. Growing consumer preference for home-based diagnostics, combined with innovation in online platforms, is creating sustained opportunities in this dynamic landscape. Riding on the coattails of these factors, the US$ 1.4 billion Europe home diagnostics market is likely to grow at 3.4% CAGR during the period 2018-2026.

Consumer Preference for Non-Invasive Glucose Monitoring Devices Still Remains Unmet 

Glucose monitoring kits and devices remain the top-selling product, accounting for over 80% revenue share of the Europe home diagnostics market. The burgeoning demand for home-based glucose monitoring devices and kits can be attributed to growing prevalence of diabetes in Europe, which is increasing across all ages according to the WHO. The Fact.MR study opines that digital devices will remain the preferred choice over cassettes among European consumers.

The broader trends pertaining to non-invasive and painless diagnostics are driving innovation in glucose monitoring device development. According to the Fact.MR study, non-invasive glucose monitoring devices are likely to witness increasing penetration in Europe, albeit at a slow pace. The report also finds that broader innovation in non-invasive devices can drive healthcare consumerism across Europe.

Request a sample of the report

https://www.factmr.com/connectus/sample?flag=S&rep_id=1892

The Fact.MR study remains optimistic on the future growth in Europe’s home diagnostics market, however, challenges prevail. “Self-testing, especially for people with type 1 diabetes, who require daily or frequent testing, remains a painful and inconvenient process. Over the decades, the innovation in glucose monitoring devices hasn’t really addressed the invasive part of the self-testing”, says Mr. Santosh Kumar, Senior Consultant at Fact.MR. “There is an urgent need for non-invasive glucose monitoring testing,” adds Mr. Kumar.

The Fact.MR study finds that home diagnostics manufacturers are aware of the evolving demand. Investment and research into developing minimally or non-invasive home diagnostics devices is gaining ground. “The realization that digital, and non-invasive devices are the future is dawning upon manufacturers. Market leaders, such as Siemens Healthcare and Abbott Technologies are leveraging wearable technologies and IoT to develop innovative products,” says Mr. Kumar.

Growth in Pregnancy and Ovulation Predictor Test Kits Sales Encouraging 

Although glucose monitoring devices and kits will account for the majority of sales, encouraging trends in other self-test kits continue to complement market growth. Pregnancy test kits and ovulation predictor test kits are likely to witness surging demand, as an increasing consumer base feels confident about self-testing. Gains are also encouraging, albeit miniscule, in other home diagnostics products, such as urinary tract infection kits and male infertility test kits.

UK Maintains its Numero Uno Position, Germany and France Remain Lucrative

The Europe home diagnostics market remains concentrated in the UK, Germany, and France. These three markets collectively account for a market share of nearly 60% revenue share of the Europe home diagnostics market. The Fact.MR study opines that these three markets will witness increasing proliferation of next-gen home diagnostics devices.

Request methodology behind the report

https://www.factmr.com/connectus/sample?flag=RM&rep_id=1892

Fact.MR study on the home diagnostics market brings interesting insights to the fore. According to the report, UK remains Europe’s largest market for home diagnostics, with revenues to the tune of US$ 280 million in 2017. The study opines that UK will maintain its numero uno position throughout the course of the forecast period 2017-2026. Germany and France will follow suit, however, sales will grow at a sluggish pace in the former.

The report also finds that home diagnostics devices that use urine and blood for testing will continue to remain pervasive in the Europe home diagnostics market. Samples devices and kits that use semen and breath are expected to witness growth during the course of the forecast period.

Buy the report

https://www.factmr.com/checkout/1892/S

SOURCE: EuropaWire

Biotech, Business of Medicine, Diagnostics, Healthcare, Healthcare Professionals, Healthcare Services, Medicine, Pathology

MEDLAB Series Europe, 13-15 Sep 2017, will cover Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology

Leave a comment

Spain, 04-May-2017 — /EuropaWire/ — After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe’s leading event for laboratory management and diagnosis.

With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024, a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content.

According to Tom Coleman, Group Exhibition Director, MEDLAB Series: “The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributors from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets.”

Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent.

The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology. From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient.

“The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region,” said Coleman.

For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com.

SOURCE: EuropaWire

Business of Medicine, Cancer, Diagnostics, Diseases, Health 2.0, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Non-Surgical Procedure, Oncology, Therapies

Multispectral Optoacoustic Tomography (MSOT) can now more reliably detect early stages of inflammation

Leave a comment

GERMANY, Mar-30-2017 — /EPR HEALTHCARE NEWS/ — Ulcerative colitis and Crohn’s disease are the most common inflammatory bowel diseases (IBD). Globally, more than 4 million people suffer from recurring inflammation of the intestinal mucosa. To date, non-invasive methods have not been able to detect these forms of IBD reliably. Researchers at the University Hospital Erlangen (Germany) have now shown for the first time how Multispectral Optoacoustic Tomography (MSOT) can more reliably detect early stages of inflammation when compared with other non-invasive diagnostic methods. These results have recently been published in the New England Journal of Medicine.

Evaluating the inflammatory activity of the intestines early and accurately helps to prevent complications associated with IBD and guide an optimal therapy regime. Currently, doctors frequently rely on an invasive endoscopy procedure to assess the intestinal mucosa of patients with IBD. Additionally, non-invasive imaging methods are increasingly used in the clinic. For example, ultrasound allows clinicians to examine the structure, thickness and blood perfusion of the intestinal wall with changes in perfusion patterns indicating an onset of inflammation.

“With the MSOT procedure, we additionally use laser light, by which we can detect inflammation earlier than previously possible with ultrasound”, explains Prof. Dr. Maximilian Waldner, Professor at the University Hospital Erlangen. “The earlier we detect signs of an upcoming flare – i.e., a change in blood content – the quicker we can react and start a preventive treatment”. The MSOT technology was developed by iThera Medical in Munich, and was first used on IBD patients last year.

The researchers of the University Hospital Erlangen have recently published their results in the renowned New England Journal of Medicine. “We examined 108 patients with Crohn’s disease using the MSOT technology and compared the results to established non-invasive diagnostic procedures as well as endoscopy and histology”, says Prof. Waldner. “We were able to demonstrate that hemoglobin values in the tissue measured with MSOT indicate very accurately the inflammatory activity in the intestines. The method appears to be superior to other non-invasive procedures, as MSOT for the first time was able to detect even low levels of inflammation without having to perform endoscopy”.

Dr. Ferdinand Knieling, a physician at the University Hospital Erlangen, adds: “We are hoping that this principle can be applied to many applications and, in particular, also be used to enable safe evaluations of children and adolescents. With this new examination method, many of the currently invasive procedures might become obsolete.”

In optoacoustic imaging, the physician scans the intestines transabdominally through the skin, applying pulsed laser light in the near-infrared region. The energy of the light absorbed in tissue is converted into acoustic signals which are then acquired by an ultrasound detector. Christian Wiest, CEO of iThera Medical, comments: “MSOT is a new diagnostic imaging modality that can detect changes in tissue composition associated with a variety of diseases, without the use of contrast agents. The technology has already been applied in other clinical feasibility studies, e.g. for the detection of melanoma metastasis in sentinel lymph nodes or for the assessment of suspicious breast lesions”.

The results of the IBD study at the University Hospital Erlangen were published on March 30th 2017 in the New England Journal of Medicine (Volume 376, Issue 13, pg.1292-1294).

SOURCE: EuropaWire

Biotech, Child health, Diagnostics, Health 2.0, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Medicine, Online, Physicians, Sports Medicine, Therapies

Sway Medical’s app for sports concussion exam received European CE Mark as Medical Device

Leave a comment

sway-concussiontest-is-a-validated-ios-app-based-concussion-management-system

TULSA, OK, 08-Sep-2016 — /EPR HEALTHCARE NEWS/ — Sway Medical is a US medical device company who’s software turns an iPhone or iPad into a mobile medical device that provides immediate medical grade, objective concussion measurement to medical professionals.

Sway Medical LLC (Sway) would like to announce its official availability in all European Union Countries. Sway was issued its CE Mark after being marketed in the United States and Canada for two years. This is significant because European sports organizations ranging from youth through pro level now have an affordable and convenient sideline assessment tool supporting concussion related medical decision making. Medical professionals and trained coaches can obtain a concussion assessment via an Apple mobile device (iPhone or iPad) and the Sway Balanceâ„¢ System web-portal. Acute objective measurements are obtained by performing a 1.5 minute balance and reaction time test protocol. Licensed athletic trainers, physical therapists and athletic therapists are able to join physicians in acutely managing the underserved market of youth sports, ages six and older.

Concussion injuries are very common in sports, often going un-reported or ignored until the obvious symptoms have incapacitated the athlete or draws the attention of a parent or coach. Second Impact Syndrome (SIS) is a serious medical condition with published mortality rates of up to 50%. SIS occurs when an athlete returns to play while still recovering from an initial concussion injury. During this time, the brain is highly susceptible to additional injury and complications. The Sway Balance™ System is able to accurately assess and track the acute and chronic outcome related to an athlete’s balance, motion reaction time and concussion symptoms. The Sway Balance™ System provides a graphical representation comparing suspicious injury event tests against a pre-injury “normative” or baseline score. The comparison of event tests against an established baseline is a common measurement for traumatic brain injury diagnosis and recovery tracking.

The Sway Balance™ System is available for purchase by licensed medical professionals involved in school, occupational or sports medicine through www.swaymedical.com. Additional protocols are available to assess an individual’s “Fall Risk” or “Functional Status”.

SOURCE: EuropaWire

Addictions, Clinics, Consultations, Diagnostics, Disorders, Healthcare, Healthcare Professionals, Healthcare Services, Psychiatry, Psychologist, Society

Private Addiction Treatment in London Now Offered by a Pilot Scheme from South London and The Maudsley NHS Foundation Trusts

Leave a comment

The Addictions Clinical Academic Group at South London and The Maudsley NHS Foundation Trust today announced a new pilot scheme offering private addiction treatment in London from their team of experts.

Nationally recognised as some of the UK’s leading addiction experts and part of the National Addiction Centre, the Maudsley team currently provide expert advice to a number of professional bodies including the GMC, the CAA, and National Air Traffic Control amongst others.

The new scheme will utilise some of their specialist addiction Consultants who will work with the private provider Clinical Partners to offer treatment to private patients in central London.

The new service will accept self-referring patients as well as referred privately funded patients from both NHS and Private Doctors and referrals from private companies. Clients are seen by the Maudsley clinicians at the Clinical Partners Wimpole Street and City consulting rooms. This is the first time that many of these distinguished clinicians have been available for patients to see privately.

The new outpatient services allow patients to continue to work while receiving the treatment they need, as well as referring those needing inpatient care to a choice of NHS and private providers. The team of Consultant Psychiatrists, Psychologists and Therapists are able to help with a wide range of addictions including alcohol, drugs, prescription medication, party drugs and sex, spending or gambling.

Mark Allen, Service Director at the Addictions Clinical Academic Group said “We’re delighted to bring some of SLAM’s expertise to this innovative new partnership between the private and public sectors.”

Barny Guthrie, CEO of Clinical Partners, said “Clinical Partners is very happy to be able to offer our clients access to some of the UK’s top addiction specialists. The Maudsley Hospital is host to a huge amount of talent and expertise and we are extremely pleased that SLAM has chosen to work with Clinical Partners.”

For further information about private addiction treatment in London or to arrange an appointment please visit http://www.clinical-partners.co.uk/how-can-we-help-you/addictions-clinic/partnership-with-maudsley-hospital

Via EPR Network
More Healthcare press releases

Business of Medicine, Diagnostics, Health Products, Healthcare, Healthcare Services, Healthcare Software, Healthcare Solutions, Hospitals

Napier Healthcare sets up US operations to address the needs of healthcare providers in North America

Leave a comment

Healthcare software solutions specialist continues its international expansion with the establishment of a wholly-owned subsidiary in the United States. The new entity will focus on driving adoption of Napier’s suite of solutions across the healthcare spectrum, including general and specialty hospitals, clinics, laboratories and blood banks.

Singapore, May 16, 2013- Napier Healthcare Solutions (www.napierhealthcare.com), a leading healthcare software provider, is pleased to announce that it has set up a wholly-owned subsidiary in the United States, Napier Healthcare Solutions, Inc.

To be based out of New Jersey, the six-member US team will be headed by Manish Mehta, an industry veteran, who will be taking charge as General Manager for the services business across America. The US entity will focus on customer acquisition across the United States and other markets in North America.

“Setting up of US operations is part of our two-pronged geographical expansion strategy, wherein we are aggressively growing our reach across emerging markets such as Africa and also establishing our footprint in developed markets such as the United States,” said Karthik Tirupathi, CEO of Napier Healthcare. “This is an important milestone in our goal to be a global provider of leading-edge software solutions for the healthcare sector.”

Targeting the US market closely follows the roll-out of Napier’s next-generation fully mobile-enabled platform Napier EHRm. This open-source based platform provides hospitals and other healthcare providers scalability, flexibility, ability to integrate with 3rd party systems and lower their total cost of ownership (TCO).

“With the new enhanced mobile platform, we are confident of offering healthcare providers in the US with a suite of solutions suitable for their diverse requirements. We believe it will be an important differentiator,” adds Karthik.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

New Study Suggests Alcohol Abuse Rewires Brain, Impedes Trauma Recovery

A recently published study suggests that heavy alcohol use may interfere with recovery from traumatic situations.

The study was published in the journal Nature Neuroscience and focused on mice that were chronically exposed to alcohol in doses twice the legal driving limit imposed on humans. Conversely, the control group of mice wasn’t exposed to any alcohol. After administering, and then ceasing, tiny electrical shocks mimicking trauma within humans, the mice chronically exposed to excessive alcohol had a more difficult time recovering from the trauma. In addition, a key receptor within the brains of the alcohol-exposed mice was suppressed and nerve cells within the brain were found to have taken on a different shape.

“This study offers valuable insight into how chronic alcohol abuse may disrupt recovery pathways in human brains,” begins a spokesperson for Mountainside Drug Rehab andAlcohol Treatment Center. “By understanding the correlation between chronic alcohol abuse and anxiety associated with traumatic events, researchers could eventually develop drugs that could assist in recovery for chronic alcohol abusers.”

The Centers for Disease Control and Prevention states that excessive alcohol use is the third leading lifestyle-related cause of death within the United States, estimating nearly 80,000 deaths annually. If you fear that a loved one may be excessively consuming alcohol, Mountainside Drug Rehab and Alcohol Treatment Center can assist them in getting their life back on track. Mountainside’s comprehensive alcohol rehab program has been recognized as a standout program among their peers.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab and alcoholism treatment facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also has available services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program and its professional addiction treatment team have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential discussion at 800-762-5433.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

Drug-Related Deaths Outnumber Deaths By Automobile Accident

The Centers For Disease Control (CDC) has declared prescription drug overdoses as an epidemic in the United States.

The CDC estimates that one death from abuse of prescription drugs happens every 19 minutes- a greater number than those killed in automobile accidents. The National Institute of Health estimates that nearly ten percent of Americans abuse narcotics over their lifetime; 20% of teens are estimated to be experimenting with opioids.

“The number of individuals who experiment with narcotics is alarming,” begins a spokesperson for Mountainside Drug Rehab and Alcohol Treatment Center. “It seems as if many individuals believe that experimenting with narcotics is safe simply because they are prescribed by a physician and filled at a pharmacy. These statistics show that these beliefs couldn’t be further from the truth. Prescription drugs are prescribed by a physician, or other qualified medical professional, for a specific individual – others abusing them are endangering their lives. We need to make certain that we are sending the right message, all of the time, to Americans. We must be vigilant as we declare war on this epidemic.”

While opioid abuse is growing at a staggering rate, there is hope. If you believe that your child or other loved one is among those who are experimenting with opioids or any other substance, Mountainside Drug Rehab and Alcohol Treatment Center can help provide professional intervention services that will help you to approach them in a non-confrontational manner.

Through their unique drug addiction treatment program, Mountainside’s team of professionals will customize a program that is unique to the specific treatment needs of the individual. In addition, their comprehensive family care program will educate the entire family as well and give them the tools to support the family member’s recovery process leading to the journey of life-long sobriety.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also has available services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

New Research Suggests Addiction to Opioids May be Preventable

A new study suggests that in the future it may be possible to eliminate possible addiction to opioids while increasing the pain relief that those medications provide.

A joint study conducted by researchers from the University of Adelaide in Australia and the University of Colorado focused on the body’s immune system response to opioids and, in particular, an immune receptor termed TLR4. This particular receptor allows the opioids to be bound to it and, by doing so, drives the physiological reward system. Researchers discovered that by creating a drug that blocks this receptor, opioids are prevented from driving the physiological reward system.

Another benefit was also discovered during this research phase. In addition to blocking the reward system pathways, researchers also discovered that the effectiveness of the opioids pain relief mechanisms also increased.

“This study deserves much consideration,” begins a spokesperson for Mountainside DrugRehab and Alcohol Treatment Center. “If it is develops that being able to increase the effectiveness of the pain relief properties of opioids while, at the same time, preventing the reward system from being activated, it will mean that those taking various pain medications will be on a safer journey.”

Statistics from the National Institute of Health estimates that nearly ten percent of Americans abuse opioids over the course of their lifetime, with one in five children experimenting with opioids prior to their seventeenth birthday. If you believe that your child is among that twenty percent and are in need of assistance in reaching your child, Mountainside Drug Rehab and Alcohol Treatment Center can help provide professional intervention services that will help you to approach your child in a non-confrontational manner.

Through their unique drug addiction treatment program, Mountainside’s team of professionals will customize a program that is unique to the specific treatment needs of the individual. In addition, their comprehensive family care program will educate the entire family as well and give them the tools to support the family member’s recovery process leading to the journey of life-long sobriety.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also has available services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential inquiry at 800-762-5433.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

Alcohol abuse may be predictable in future

A new study conducted by researchers at the University of California found that future prediction of alcohol abuse might be possible.

MRI scans were performed on 40 adolescents who had never drank alcohol and found that the children who had been followed, initially, showed less activity in specific areas of the brain and were at potential risk for becoming heavy drinkers.

“While this study followed adolescents, it provided valuable insight into the brain’s mechanisms,” begins a spokesperson for Mountainside Drug Rehab and Alcohol Treatment Center. “Certainly, this study doesn’t advocate brain scans for adolescents, but research into the way these specific areas of the brain function may be able to help those within the addiction field to look into means for advanced prevention for alcohol abuse in the future within a variety of ages of individuals.”

Prevention, beginning at a young age, is the key to decreasing alcohol abuse in America.

As a parent, you may find it difficult to approach your child about issues relating to alcohol or to their drinking. However, if you suspect that your young adult is struggling with underage drinking, Mountainside Drug Rehab and Alcohol Treatment Center can help you gently and effectively approach them with their customized, professional intervention services.

Through their unique alcohol rehab treatment program, their team of professionals will customize a program that’s unique to the specific treatment needs of the individual. Their comprehensive family care program will educate the individual and his/her family and provide the necessary tools to support the recovery process.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also has available services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities that Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential inquiry at 800-762-5433.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

New FDA Regulations Require More Of Opioid Drug Makers

In an effort to help decrease the number of deaths related to opioid overdose, the FDA is requiring pharmaceutical companies that manufacture opioids to help fund training programs for medical professionals. Along with the training funding, drug makers will also be required to provide safety pamphlets to patients explaining the risks and interactions of the opioids.

“The FDA’s new measure will hopefully prove to be an effective means to decrease overdose due to the misuse of prescription drugs,” begins a spokesperson for Mountainside Drug Rehab and Alcohol Treatment Center . “Education of patients is particularly important. Some may think that the risk of overdose and the misuse of narcotics are widely known. However, we believe that some individuals still believe that taking just a few extra pills can’t hurt. In fact, that’s simply not true; taking a few extra pills can be the difference between life and death.”

In the past decade, overdose death rates within the United States have more than tripled. While a narcotic addiction can start off innocently, it can quickly become an acute, dangerous addiction. If you are concerned that your narcotic use may be spiraling out of control, Mountainside Drug Rehab and Alcohol Treatment Center can help you get, and stay, on the road to recovery. Through their unique addiction treatment program, their team of professionals will customize a program that’s unique to your specific treatment needs. Their comprehensive family care program will educate your family as well and give them the tools to support your recovery process and help you on your journey to life-long sobriety.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also provides services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential inquiry at 800-762-5433.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

July 4 Is Among The Most Deadly Holidays In The US

While many are celebrating the anniversary of the independence of the United States, others are suffering tragedy.

The state of Louisiana reports that more than half of their state’s motor vehicle crashes occur during the Fourth of July holiday, and the numbers increase annually.

“Many states report the same tragic situation that takes place in Louisiana,” begins a spokesperson for Mountainside Drug Rehab and Alcohol Treatment Center. “Fortunately, in response to the growing number of fatal motor vehicle accidents, Highway Patrols in many states are setting up additional sobriety checkpoints and saturation patrols during this holiday period, as well as other holiday periods. While these methods certainly have the potential to reduce fatalities, the best method is to be pro-active with prevention.”

Tips for being pro-active in prevention for the Fourth of July holiday:

•  Designate yourself as the sober driver. Don’t wait for someone to volunteer to become the designated driver. Let your friends know that you are the point of contact for all transportation needs during the Fourth of July celebratory events.

•  Limit the amount of alcohol served to everyone. Limiting the number of drinks served to everyone changes the atmosphere of the party from one of intoxicated people to one in which everyone is having fun and not getting intoxicated.

•  Make plans to stay put. While this may seem like an extreme measure, if you’re hosting a celebration, arrange for a place for some guests to crash in the event they drink too much.

Holiday times can be a particularly challenging and eye-opening time for those who abuse drugs and alcohol and can be used as a catalyst for change in the life of an addicted individual. If you are interested in helping a friend or loved one recover from their addiction, Mountainside Drug Rehab and Alcohol Treatment Center can assist you with professional intervention services. Upon admission, Mountainside will help create an individualized drug and alcohol abuse program that fits each individual’s needs and helps them get on the road to a sober life. In addition, its comprehensive family care program gives you and your family the tools needed to help support you in your recovery journey.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also provides services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential inquiry at 800-762-5433.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

Importance Of Individualized Drug Rehab Highlighted

Leave a comment

Within the field of addiction treatment many methodologies are available for rehabilitation. But, none are quite as effective as the approach used by one particular drug rehab located in Canaan, CT.

In its humble beginnings, Mountainside Drug Rehab and Alcohol Treatment Center set out to provide innovative and individualized treatment. Through its evidence-based treatment modalities, supported by new innovative treatment modalities, Mountainside created a rehab model that sets the course for lifelong sobriety success for those entering into the Mountainside treatment program. This newfound approach was relatively simple in nature: individualized treatment for each person.

“At its core, our rehab program is very straightforward,” begins a spokesperson for Mountainside Drug Rehab and Alcohol Treatment Center. “Each person who enters into rehab is unique – they bring their own set of circumstances into treatment and, because of that, there’s no exclusive treatment model that fits everyone. When a person enters into our rehab program our team of clinical professionals completes a thorough assessment and then is able to create a program that addresses the uniqueness of each person. Some individuals who enter into treatment present with dual diagnoses; this requires the services of a psychiatrist to help with an underlying problem that may be contributing to the addiction. Other individuals may enter into treatment experiencing massive withdrawals from their substance of choice, necessitating a physical detox. Whatever the need, we are able to create an individual course of action which establishes a solid foundation for long-term sobriety success.”

If you or a family member is struggling with a substance abuse problem, Mountainside Drug Rehab and Alcohol Treatment Center can help you by creating an individualized treatment program that addresses your specific needs for recovery. Our outstanding family care program provides the comprehensive services that families need when dealing with an addiction or alcoholism issue by giving families the tools necessary to rebuild their bonds of unity. Mountainside’s treatment recovery program is recognized as one of the most comprehensive and individualized programs within the addiction treatment field.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also provides services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential inquiry at 800-762-5433.

Via EPR Network
More Healthcare press releases

Addictions, Clinics, Diagnostics, Drugs, Healthcare, Healthcare Information, Healthcare Services, Medicine, Rehab, Society, Therapies

New State Law Hopes To Limit Detrimental Effects Of Underage Drinking

Leave a comment

A new Indiana state law, signed into effect by Governor Mitch Daniels, offers protection from prosecution for some minor alcohol-related offenses.

The law goes into effect on July 1, 2012 and offers protection for individuals who may be publically intoxicated or who are underage drinkers and are seeking help for another person who is facing an alcohol-related emergency.

“This law should be seen as a way to help save lives of underage drinkers,” begins a spokesperson for Mountainside Drug Rehab and Alcohol Treatment Center . “Sometimes, a group of underage students will join with others at a party, consuming a great deal of alcohol, and someone will fall critically ill due to excessive alcohol consumption. The tendency would be for the participants to protect themselves to the detriment of the person who needs medical attention. Under this new law, if a fellow underage drinker helps another potentially critically ill underage drinker, neither will be prosecuted. While we need to send the message for those who are underage to abstain from drinking alcohol entirely, we also need to make certain that those who have consumed too much alcohol do get the medical help that they need.”

The new Indiana law, called the Lifeline Law, provides immunity, as long as the person reporting the incident cooperates fully with police and other law enforcement officials, provides his or her contact details, including full name, and he or she must remain at the scene until police or the paramedics arrive. The message that this law hopes to send is that even if you have illegally consumed alcohol, one’s primary goal is to save the life of another person in peril.

Underage college drinking, which includes binge drinking, has claimed the lives of so many young people and will continue to do so until those at risk receive vital alcoholism treatment. Fortunately, Mountainside Drug Rehab and Alcohol Treatment Center specializes in helping individuals get on the road to recovery through their holistic drug rehab and alcoholism treatment programs. Their evidence based holistic treatment models are among the most effective for long term sobriety and are recognized among the most comprehensive and individualized programs within the addiction treatment field.

Mountainside Drug Rehab and Alcohol Treatment Center is a modern drug rehab facility that is skilled in serving a variety of clients with various addictions and in varying stages of addiction. The caring, compassionate team is made up of licensed and certified social workers and counselors who have extensive experience and specialty in the addiction treatment field. In addition, the staff includes a Nurse Practitioner, as well as a Registered Nurse, both of whom also have specializations and experience within the field of addiction treatment and alcohol rehab.

Mountainside also provides services for those individuals who come to them with dual diagnoses and require the services of a Psychiatrist to help conquer the unique challenges that dual diagnosis brings.

For the past 13 years, Mountainside has established itself as an innovator within the addiction treatment field, and the treatment modalities Mountainside utilizes are regarded as among the most cutting-edge approaches in helping individuals to get, and to remain, sober. As a result of their unique, innovative approaches to addiction treatment, Mountainside has become the model for the addiction treatment field.

The program, along with its professional addiction treatment team, have earned national recognition and resulted in Mountainside being invited to Washington by the White House to meet with the White House Drug Czar, John P. Walters, for an in-depth meeting on what makes its program so successful. These accolades did not go unnoticed within the addiction treatment field and resulted in the adoption by many throughout the country of a more holistic approach to drug addiction treatment.

If you or someone you love is addicted to drugs or alcohol, or if you have any questions, please contact Mountainside Drug Rehab and Alcohol Treatment Center for a confidential inquiry at 800-762-5433.

Via EPR Network
More Healthcare press releases